A 12 WEEK RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE AND PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06650833 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Zimlovisertib (Primary) ; Tofacitinib
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 09 Sep 2018 Status changed from active, no longer recruiting to completed.
- 05 Sep 2018 This trial was completed in Slovakia (end date: 2018-08-15), according to European Clinical Trials Database.
- 29 Aug 2018 This trial was completed in Czech Republic (end date: 2018-08-15), according to European Clinical Trials Database.